Conclusions: Calls to action for improving the life of MS patients and their families
- PMID: 27465617
- DOI: 10.1177/1352458516650738
Conclusions: Calls to action for improving the life of MS patients and their families
Abstract
Background: The first and second Pan-European MS Multi-stakeholder Colloquia were set up to increase cross-talk and communication between the different stakeholders in MS and developed joint Calls to Action to improve (equal) access to quality care and treatment for MS in Europe.
Objective & methods: To summarise the 10 integrated and interrelated Calls to Action developed.
Results & conclusion: Call 1: increase awareness in the European community about the burden MS places on patients, caregivers and society. Call 2: improve communication towards the European community on the direct and indirect cost burden of MS. Call 3: perform patient research to (re)define treatment goals/endpoints from a humanistic/patient perspective point of view. Call 4: develop new tools to better capture the total clinical burden of MS. Call 5: develop a protocol for standardisation of MRI for optimising its use as a marker of disability progression in MS. Call 6: support research to find other (molecular) biomarkers which can predict long-term disability progression and (monitor) individual treatment response. Call 7: align CHMP/EMA and HTA decision-making process. Call 8: develop separate EMA guidelines for evaluating follow-on products of non-biological complex drugs. Call 9: support people with MS remaining (physically) active and at work and stimulate the implementation of specialised care centres. Call 10: support the continuation of multi-stakeholder colloquia.
Keywords: Multiple sclerosis; clinician; multi-stakeholders; patient; payer; regulator.
© The Author(s), 2016.
Similar articles
-
Introduction: Do we need multi-stakeholder colloquia in MS?Mult Scler. 2016 Aug;22(2 Suppl):4-8. doi: 10.1177/1352458516650740. Mult Scler. 2016. PMID: 27465611
-
The payer's perspective: What is the burden of MS and how should the patient's perspective be integrated in health technology assessment conducted for taking decisions on access to care and treatment?Mult Scler. 2016 Aug;22(2 Suppl):60-70. doi: 10.1177/1352458516650743. Mult Scler. 2016. PMID: 27465616 Review.
-
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this?Mult Scler. 2016 Aug;22(2 Suppl):18-33. doi: 10.1177/1352458516650739. Mult Scler. 2016. PMID: 27465613 Review.
-
The importance of a multi-disciplinary perspective and patient activation programmes in MS management.Mult Scler. 2016 Aug;22(2 Suppl):34-46. doi: 10.1177/1352458516650741. Mult Scler. 2016. PMID: 27465614 Review.
-
The patient's perspective: How to create awareness for improving access to care and treatment of MS patients?Mult Scler. 2016 Aug;22(2 Suppl):9-17. doi: 10.1177/1352458516650742. Mult Scler. 2016. PMID: 27465612
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous